The moment follows, though was far less pronounced than, an incident in February where he suffered a seizure while delivering ...

Xenon Pharmaceuticals Inc.'s XEN1101 shows promise in epilepsy with strong phase 2b results and solid financials. Click here ...

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

For more information on NeuroPace and the RNS System, join us at booth #1642 at the 2025 AAN Annual Meeting or visit https://www.neuropace.com.

The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, ...

The 15th Hockey India Senior Men National Championship 2025 will be held from April 4-15 in Jhansi, Uttar Pradesh, featuring ...

NeuroPace gross margin is expected to increase as the margin for SEEG distributed products is approximately 50%, while the margin of the RNS System is over 78%.

A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple ...

Mayo Clinic is taking epilepsy research in a bold new direction, exploring treatment approaches to help patients living with the most severe and difficult-to-treat forms of epilepsy. About 50 million ...

Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases. Check out my recommendation ...

Childhood epilepsy is more than seizures. Learn to recognize symptoms, manage triggers, and support your child’s well-being.